Biotie and Seikagaku part ways
This article was originally published in Scrip
Finnish firm Biotie Therapies and Seikagaku of Japan are terminating their licence agreement for Biotie's VAP-1 antibody programme. The licence, under which Biotie had granted Seikagaku exclusive rights for development and commercialisation of the VAP-1 monoclonal antibody BTT-1023 in Japan, Taiwan, Singapore, New Zealand and Australia, was signed in April 2003 and was built around Seikagaku's expertise in locomotive diseases such as osteoarthritis.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.